Research Article
1 March 2007

Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species

ABSTRACT

The minimum effective concentration (MEC) used to assess the in vitro antifungal activity of caspofungin against Aspergillus spp. is a qualitative endpoint requiring microscopic examination of hyphae. We therefore developed a tool for the quantitative assessment of caspofungin activity against Aspergillus spp. at clinically applicable concentrations. Susceptibility to caspofungin (0.008 to 8 μg/ml) was studied for 9 A. fumigatus, 8 A. flavus, and 12 A. terreus isolates based on the Clinical and Laboratory Standards Institute M38-A protocol. After 48 h of incubation, the MEC was defined microscopically, and metabolic activity assessed with a modified XTT assay, using 100 μg of the tetrazolium salt XTT/ml and 6.25 μM menadione. A significant reduction in metabolic activity was demonstrated at the MEC (0.25 to 0.5 μg/ml) for all Aspergillus spp. and was more pronounced for A. flavus (median metabolic activity, 25% of control) compared to A. fumigatus and A. terreus (median metabolism, 42 and 53%, respectively), allowing determination of MEC with the XTT assay (93 to 100% agreement with microscopic MEC). Fungal metabolism tended to reach the lowest levels (median, 17 to 38% of control) one to two dilutions higher than the MEC, at the minimum metabolic activity concentration (MMC). For 5 of 9 A. fumigatus isolates, 6 of 12 A. terreus isolates, and 1 of 8 A. flavus isolates, a paradoxical increase in metabolism was observed at concentrations greater than the MMC. Sigmoid (Emax) or bell-shaped models described accurately (median R2 = 0.97) the concentration-dependent metabolic changes in the absence or presence, respectively, of paradoxical response. Assessment of metabolic activity may provide useful quantitative endpoints for in vitro studies of caspofungin against Aspergillus spp.
Echinocandins are lipopeptide antifungal compounds that inhibit the (1,3)-β-d-glucan synthase activity of Candida spp. and Aspergillus spp. Caspofungin has shown efficacy in the treatment of invasive candidiasis and aspergillosis in vivo and in clinical trials and is currently the most widely used echinocandin (1, 11, 13, 16, 21).
Assessment of in vitro activity of caspofungin against Aspergillus spp. is complicated by the fact that the MIC often exceeds safely achievable plasma concentrations, which range approximately between 1 and 11 μg/ml in adults receiving 50 mg/day and between 1 and 20 μg/ml in children receiving 50 mg/m2/day (11, 12, 25, 27). The minimum effective concentration (MEC), defined as the lowest drug concentration at which short, stubby, and highly branched hyphae are observed on microscopic examination has been shown to generate more consistent susceptibility results than the MIC and is currently the suggested endpoint for determining the in vitro activity of caspofungin against Aspergillus spp. (3, 11, 12, 20).
The MEC endpoint, however, still represents a subjective assessment of the appearance of growth and cannot be automated. Its determination requires laborious microscopic examination of the hyphal structures or sufficient expertise for macroscopic appreciation of the presence of round microcolonies in the wells (3, 9). In a multicenter study evaluating caspofungin susceptibility testing, 3 of 17 laboratories generated inconsistent results using MEC determination (20). Furthermore, the MEC is an endpoint that is based upon qualitative assessment of hyphal morphology and, as such, it does not provide quantification of caspofungin activity at different concentrations. For example, using the MEC as an endpoint may be problematic for in vitro antifungal combination studies, in which the detection of significant drug interactions may require the use of more sensitive, quantitative methods that could demonstrate a concentration-effect relationship for caspofungin activity against this organism (29). Thus, in order to better understand the in vitro activity of caspofungin against Aspergillus spp. across the range of clinically achievable concentrations, new quantitative tools are needed beyond the MIC and MEC.
We therefore developed a new, quantitative method for the assessment of in vitro activity of caspofungin against Aspergillus spp. at clinically relevant concentrations. For this purpose, we studied the changes in metabolic activity of Aspergillus spp. in the presence of increasing caspofungin concentrations by using an optimized XTT assay, in which the concentration of the electron transfer agent, menadione, was modified in order to detect concentration-dependent effects in fungal metabolism. We subsequently correlated the changes in metabolic activity with the microscopically defined MEC for Aspergillus fumigatus, A. terreus, and A. flavus. Finally, we modeled the changes in metabolic activity in the presence of clinically achievable caspofungin concentrations in order to generate predictive concentration-effect curves, to quantify interspecies differences, and to facilitate data analysis for future in vitro and in vivo studies with caspofungin.

MATERIALS AND METHODS

Isolates.

A total of 29 clinical isolates of Aspergillus spp. was used, including 9 isolates of A. fumigatus, 12 isolates of A. terreus, and 8 isolates of A. flavus. Conidia were harvested after isolates were subcultured on potato dextrose agar at 35°C for 5 to 7 days and were suspended in normal saline containing 0.025% Tween 20. Conidial suspensions were counted with a hemacytometer, and inoculum sizes were verified by quantitative colony counts on Sabouraud dextrose agar plates. Reference strains Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were used as quality controls.

Medium.

RPMI 1640 medium with l-glutamine but without bicarbonate, buffered to pH 7.0 with 0.165 M 3-N-morpholinopropanesulfonic acid (Cambrex BioScience, Inc., Walkersville, MD), was used as the assay medium.

XTT and menadione.

The tetrazolium salt XTT (Sigma-Aldrich, St. Louis, MO) was dissolved in normal saline at 0.5 mg/ml. Menadione (Sigma-Aldrich) was dissolved in absolute ethanol at 10 mg/ml (58 × 10−3 M) and subsequently added to the XTT solution at concentrations of 125, 31.25, or 7.8 μM.

Susceptibility testing.

Susceptibility to caspofungin was studied for all Aspergillus isolates using the broth microdilution method based on the CLSI M38-A protocol (19). Caspofungin (Merck & Co., Inc., Whitehouse Station, NJ) was dissolved in sterile water. Twofold serial dilutions in the assay medium were initially prepared in flat-bottom 96-well microtitration plates (Costar 3596; Corning, Inc., Corning, NY) in order to obtain final concentrations ranging from 0.008 to 8 μg/ml at a total volume of 200 μl after inoculation. The range of concentrations studied was chosen based on human pharmacokinetic studies (25, 27). After inoculation of caspofungin trays with a final concentration of 2.5 × 104 conidia/ml and incubation at 37°C for 48 h, the MEC was defined microscopically as the lowest drug concentration that produced short, stubby, and highly branched hyphae (3, 9). In each tray, a row of wells was filled with RPMI 1640 up to a total volume of 200 μl, without fungal inoculum, and served to provide background absorbance values in subsequent spectrophotometric measurements of XTT conversion. The experiments were repeated in triplicate. For reasons of clarity, the use of the term MEC throughout the text implies the microscopically determined MEC, whereas the term X-MEC implies that this value was determined with the XTT assay (see below).

Optimization of XTT assay for assessment of metabolic activity.

For six Aspergillus isolates (two of each species), immediately after MEC determination 50 μl of the XTT-menadione solutions described above was added to each well, resulting in final concentrations of 100 μg of XTT/ml and 25, 6.25, or 1.56 μM menadione. The plates were incubated at 37°C for 2 h and subsequently shaken for 1 to 2 min (Wallac Plate Shake 1296-004; Wallac OY, Turku, Finland) for further dissolution of the formazan derivatives (2, 14). Color absorbance (A) was then measured at dual wavelengths (450 and 630 nm [reference] in order to correct for the absorbance of hyphae) with a microtitration plate spectrophotometric reader (Elx808; Bio-Tek Instruments, Winooski, VT). The percent metabolic activity for each drug well in relation to the drug-free control was calculated after subtraction of the background absorbance as follows: % metabolic activity = (Adrug wellAbackground drug well)/(AcontrolAbackground control) × 100%. For each isolate, the measurements obtained using different menadione concentrations were evaluated with respect to the changes in the percent metabolic activity observed at or one to two wells near the MEC, as well as the degree of experimental variability.
After obtaining the results of these studies (see Results), we additionally investigated whether performing the XTT assay with the higher menadione concentration (25 μM) but shorter incubation period (30 min or 1 h) would yield changes in the percent metabolism at the MEC that would be comparable to those detected using 6.25 μM menadione and a 2-h incubation. For this purpose the six isolates mentioned above were studied, and the XTT assay was performed as described above, with shorter incubation times for the plates to which 25 μM menadione had been added.

Concentration-dependent effects of caspofungin on Aspergillus spp.

Following the above studies of optimization of the XTT assay (see Results), the metabolic activity in the presence of increasing concentrations of caspofungin for the greater collection of Aspergillus isolates was assessed using final concentrations of 100 μg of XTT/ml and 6.25 μM menadione and a 2-h incubation time. The XTT assay was performed as described above, immediately after microscopic MEC determination at 48 h of incubation. For each isolate, the percent metabolic activity obtained at the MEC was recorded. The caspofungin concentration at which the metabolic activity reached its lowest values was also recorded and, for the purpose of the present study, is referred to as the minimum metabolic activity concentration (MMC). In case a paradoxical increase in metabolic activity was observed at higher caspofungin concentrations, it was considered significant if it exceeded the metabolic activity at MMC by at least 40% and was consistent in all three experiments. The cutoff of 40% was used based on previous data demonstrating a coefficient of variation up to 19% for the spectrophotometric measurements of XTT conversion (15). For each species the values of the percent metabolic activity at 8 μg of caspofungin/ml were compared to those at the MMC.

Determination of X-MEC by the optimized XTT assay.

The assessment of the percent metabolic activity corresponding to the microscopic MEC for each Aspergillus isolate allowed the development of a method for the determination of the X-MEC by using the optimized XTT assay (100 μg of XTT/ml and 6.25 μM menadione). Determination of the X-MEC required the use of cutoff values of the percent metabolism (compared to drug-free control) at 48 h that were based on the best agreement obtained between the microscopic MEC and X-MEC values, as described below. Starting from the median value of the percent metabolism at the microscopic MEC obtained for each species, a range of values of metabolic activity in increments of 5% (± from the median) were evaluated as cutoff levels for this purpose. The XTT endpoint (i.e., the X-MEC) was defined as the lowest caspofungin concentration showing a percent metabolic activity equal to or less than the value evaluated as cutoff level. For each species, values of percent metabolic activity for which the best relative agreement (± one dilution) was obtained between the X-MEC and microscopic MEC were defined as cutoff levels for determination of X-MEC with the optimized XTT assay.

Modeling of caspofungin effects on the metabolic activity.

The choice of model for description of the concentration-effect relationship between the caspofungin concentration and metabolic activity for Aspergillus spp. depended on the presence or absence of a paradoxical increase of fungal metabolism at higher concentrations.
For isolates for which a paradoxical response was not detected, the Emax model (sigmoid curve with a variable slope) was used. This four-parameter logistic model is described by the equation: Y = Ymin + (Ymax − Ymin)/[1 + 10(logEC50-X)*slope], where X is the log10 of the caspofungin concentration, Y is the corresponding percent metabolic activity, and the four parameters are the values of the maximal (Ymax) and minimal (Ymin) percent metabolic activities, respectively, the EC50, which is the drug concentration showing metabolic activity that is halfway between the Ymax and Ymin, and the slope, which describes the steepness of the curve (18).
For isolates demonstrating a paradoxical increase in metabolic activity at higher caspofungin concentrations, two different models were evaluated and compared. The first model combines two sigmoid concentration-effect relationships to describe what looks like a bell-shaped curve based on the equation: Y = Ymin + (Ymax1 − Ymin)/[1 + 10(logEC50_1-X)*nH1] + (Ymax2 − Ymin)/[1 + 10(logEC50_2-X)*nH2], where X is the log10 of caspofungin concentration and Y is the corresponding percent metabolic activity (17). The biphasic curve begins at Ymax1, turns over at Ymin, and then approaches Ymax2. EC50-1 and EC50-2 are the corresponding EC50 values for each phase of the curve, while the model includes two more parameters, the slope factors nH1 and nH2 for each phase of the curve. The problem, however, with the bell-shaped equation is that it is a complicated model, requiring a sufficient number of datum points to adequately define its seven parameters and, consequently, both phases of the response to the drug. For this reason, the possibility of a simpler model that could still describe such a biphasic concentration-effect relationship was also investigated. A relatively simple model for this purpose is based on the following equation that describes the Gaussian distribution: Y = Ymax − range*exp(−1*[(X-midA)/slope]2), where midA is the logEC50 − slope*[−ln(0.5)]. This model includes only four parameters: the maximal response (Ymax), the logEC50, the range (i.e., the difference between the maximal and minimal response), and the slope. Since the Gaussian model requires fewer parameters than the bell-shaped model, it can be used to fit concentration-effect curves with fewer datum points. An important limitation of the Gaussian model, however, is its symmetric nature, implying that both phases of the curve are mirror images (17).
For each of the isolates demonstrating a paradoxical effect, direct comparison of the above two models (bell-shaped and Gaussian) was performed by using the corrected Akaike's information criterion (6). The latter is a valid method for comparing models that is based on information theory and tells which model is more likely to explain the data by balancing the improvement in goodness-of-fit (R2), obtained by using a more complex model, with the increase in the number of parameters. Model building was performed by using GraphPad Prism software (4.0b; San Diego, CA).

Statistical analysis.

Comparisons of metabolic activity at the MEC or MMC among Aspergillus species were performed by nonparametric analysis of variance, using the Kruskal-Wallis test, followed by Dunn's test for multiple comparisons. In order to compare the metabolic activity at 8 μg of caspofungin/ml versus MMC for each species, a Wilcoxon matched-pairs test was used (GraphPad Prism Software 4.0b). A P value of <0.05 was considered statistically significant.

RESULTS

Susceptibility testing.

MICs for quality control strains were within reference range, and the MEC ranged from 0.25 to 0.5 μg/ml for all Aspergillus isolates (Table 1) .

Optimization of XTT assay for assessment of metabolic activity.

In the initial 2-h incubation experiments, when the higher concentration (25 μM) of menadione was used, no significant change in the percent metabolic activity of A. terreus and A. flavus isolates was detected in the presence of increasing caspofungin concentrations, whereas for A. fumigatus the reduction in metabolic activity did not exceed 40% at concentrations greater than or equal to the MEC. With the lower concentration of 6.25 μM menadione, however, a clear reduction in fungal metabolism was detected at caspofungin concentrations greater than or equal to the MEC for all three species. This reduction was on the order of 70 to 80% for the A. fumigatus and A. flavus isolates used in these preliminary studies and 50% for A. terreus. Interestingly, for both A. fumigatus and one of the two A. terreus isolates a paradoxical increase in metabolic activity was observed at higher caspofungin concentrations (Fig. 1). When 1.56 μM menadione was used, the concentration-dependent changes in metabolic activity were similar to those obtained with 6.25 μM. However, low XTT conversion rates (absorbance of 0.2 to 0.3) were frequently observed with the 1.56 μM concentration, which resulted in increased variability in the calculated percent metabolic activity (data not shown).
Using incubation for 1 h or 30 min and 25 μM menadione, we found that the reduction in the percent metabolism detected at the MEC was progressively increased with shorter periods of incubation and at 30 min, for three of the six isolates, it was comparable to that detected using 6.25 μM menadione and a 2-h incubation. However, for the other three isolates very low absorbance values were observed (0.1 to 0.2), resulting again in significant interexperimental variability in the obtained values for the percent metabolic activity.
Consequently, a menadione concentration of 6.25 μM and an incubation time of 2 h were considered to be the optimal conditions for assessment of the caspofungin effects on the metabolic activity of the greater collection of Aspergillus isolates using the XTT assay.

Concentration-dependent effects of caspofungin on Aspergillus spp.

For all Aspergillus isolates, a substantial reduction in metabolic activity was associated with the formation of short, aberrant hyphae in the presence of caspofungin. As demonstrated in Table 1, this reduction was more pronounced (P < 0.01) for A. flavus (median metabolism = 25% of control) compared to A. fumigatus and A. terreus (median metabolic activities of 42 and 53%, respectively). For most isolates, the MMC tended to be one to two dilutions higher than the MEC. The intraspecies range of MMC values appeared to be broader than the MEC values; however, for each isolate the interexperimental variability of MMC rarely exceeded one dilution. The interspecies differences in the metabolic activity recorded at the MMC paralleled those observed for the MEC, with A. flavus exhibiting greater metabolic inhibition than A. fumigatus and A. terreus (P < 0.01). Both at the MEC and at the MMC, significant and reproducible intraspecies variation in the metabolic activity was demonstrated, mainly for A. fumigatus and A. terreus (Table 1).
For approximately half of the A. fumigatus and A. terreus isolates a gradual increase in metabolic activity was observed at caspofungin concentrations higher than the MMC, suggesting a paradoxical effect. This paradoxical increase was infrequent for A. flavus (Table 1). For A. fumigatus and A. terreus isolates, the average metabolic activity at 8 μg of caspofungin/ml was increased by factors of 1.82 and 1.47, respectively, compared to that of MMC (P < 0.001 for both species), whereas for A. flavus it was increased by 1.15, which was not statistically significant.

Determination of X-MEC by the optimized XTT assay.

The significant reduction in fungal metabolism detected at the MEC for Aspergillus spp. could allow determination of X-MEC with the optimized XTT assay. However, because of the interspecies differences in the observed metabolic activity at the microscopic MEC (Table 1), the values of the percent metabolic activity that could serve as cutoff levels for X-MEC determination would have to be different for each Aspergillus species. Indeed, the cutoff levels of the percent metabolism that gave the best relative agreement (± one dilution) with the microscopically determined MEC were different for each species. Using these cutoff levels, the agreement between the X-MEC and microscopic MEC ranged between 93 and 100% (Table 2).

Modeling of caspofungin effects on the metabolic activity.

For isolates for which a paradoxical response was not detected (i.e., most of the A. flavus and approximately half of the A. fumigatus and A. terreus isolates, a total 17 of 29 isolates), the data were well described with the Emax model, as demonstrated by R2 values ranging between 0.87 and 0.99 (median = 0.97), and no significant deviations with the runs test.
The median (range) of minimal (Ymin) values of the percent metabolism calculated with the Emax model for the above isolates was 35% (21 to 60%) for A. fumigatus, 44% (27 to 77%) for A. terreus, and 20% (12 to 27%) for A. flavus, demonstrating again a greater reduction of metabolic activity for A. flavus compared to other species, in agreement with the findings presented in Table 1. The generated sigmoid curves were steep, as manifested by the high absolute numbers of the (negative) slope factors, which ranged from 4.39 to 35.5 (median = 7.1) without significant interspecies differences. For all isolates, the metabolic activity corresponding to the microscopic MEC was lower than that of EC50, approximating the Ymin. However, because of the steepness of the sigmoid curves, the EC50 and MEC values for every isolate were very close (Fig. 2A). Thus, while the MEC values ranged between 0.25 and 0.5 μg/ml (Table 1), the EC50 values ranged between 0.14 and 0.48 μg/ml. In addition, the ratio MEC/EC50 ranged from 1.03 to 1.93 (median = 1.40), suggesting that the microscopic MEC tended to be slightly higher than the EC50, but their difference would not exceed one twofold dilution. Consequently, the EC50 values generated by the Emax model provided a very good approximation (within one dilution) of the MEC values. These findings suggest that modeling of data and calculation of EC50 values could provide an alternative way for determination of X-MEC with the optimized XTT assay, without the use of the cutoff levels presented in Table 2.
For the remaining 12 isolates for which a paradoxical increase was detected at higher caspofungin concentrations (Table 1), the bell-shaped model was able to fit the data very well, as manifested by high R2 values (0.85 to 0.99 [median = 0.97]) (Fig. 2B). The absolute values of slope factors (nH1) of the first phase of the biphasic curve (associated with the MEC) ranged between 2.28 and 39.92 (median: 6.48) and were comparable to those reported above for the Emax model. However, the second phase of the curve (associated with the paradoxical effect) tended to be less steep, as manifested by lower values of the corresponding slope factors (nH2), which ranged from 0.73 to 8.32 (median = 1.53). As with the Emax model, the derived EC50-1 values ranged between 0.15 and 0.67 μg/ml and were always within one dilution from the microscopic MEC (Fig. 2B). In the present study, the number of 12 datum points (11 concentrations of caspofungin plus drug-free control) was small relative to the number of seven parameters defined by the bell-shaped equation. Consequently, appropriate initial parameter values needed to be chosen in order to assure that the model converged successfully. Furthermore, wide confidence intervals were sometimes obtained for the best-fit values of some of the parameters (mainly those describing the second phase of the curve).
In contrast to the bell-shaped equation, the relatively simple Gaussian model easily converged for all isolates demonstrating the paradoxical response, and its parameters were well defined. Its symmetric nature, however, proved to be a disadvantage for description of the asymmetric biphasic concentration-effect curve observed with caspofungin, in which the first phase was usually steeper than the second. Consequently, the Gaussian equation did not appear to fit the data as well as the bell-shaped model did (Fig. 3). This problem was also demonstrated by the R2 values, which ranged between 0.78 and 0.96 (median = 0.89) (i.e., lower than the corresponding values for the bell-shaped model). Direct comparison of the two models for each of the 12 isolates using the corrected Akaike's information criterion suggested that the bell-shaped model was more adequate to describe the data than the Gaussian equation in 8 of the 12 comparisons.

DISCUSSION

There are few reports published to date in which the XTT method was used for assessment of metabolic activity of Aspergillus spp. in the presence of caspofungin (26, 28, 29). These studies, however, did not aim at a comprehensive description of the concentration-dependent effects of caspofungin on the metabolic activity of this organism, and consequently the number of isolates for which the assay was performed was limited (six isolates for all three studies). Furthermore, the final concentrations of menadione used ranged from 25 to 50 μM, resulting in a very small reduction of XTT conversion at the MEC, on the order of 10 to 45% for A. fumigatus, 10% for A. terreus, and 26% for A. flavus (26, 28, 29). These findings are consistent with those of the present study, in which, using a 2-h incubation period and 25 μM menadione, no significant change in metabolic activity was detected at the MEC for A. terreus and A. flavus, whereas for A. fumigatus the reduction did not exceed 40%.
Lower menadione concentrations (6.25 and 1.56 μM) were required to detect a substantial decrease in the metabolic activity associated with the formation of aberrant hyphae for all species. This apparently intriguing finding could be explained by the role of the menadione concentration, which is the electron transfer agent, in the relationship between XTT conversion and viable fungal biomass. In a previous study, using various concentrations of menadione and a 2-h incubation period, we found a sigmoid relationship between metabolic activity and fungal biomass for zygomycetes. We demonstrated that beyond certain values of viable biomass there is no further increase in XTT conversion, which reaches a plateau. With higher (25 μM) menadione concentrations this plateau is reached at lower values of biomass, while with 6.25 or 1.56 μM the plateau is reached later (2). Consequently, even if there is a true reduction of viable biomass to 50% of control, the corresponding XTT conversion using 25 μM of menadione may still have reached its plateau, yielding an absorbance of 90 to 95% of control, and the real magnitude of decrease may be missed. Thus, lower menadione concentrations seem to be more appropriate in order to detect and quantify partial inhibition of fungal viability, as is the case for Aspergillus spp. in the presence of caspofungin.
One of the findings of the present study was that the metabolic activity of the Aspergillus spp. tended to decrease further at caspofungin concentrations one to two dilutions higher than the MEC, and for this purpose the term MMC was introduced. The intraspecies variation of MMC was greater than that of MEC values; the implications of this finding and its correlation with in vivo outcome remain to be investigated. Of probably greater significance could be the noticeable inter- and intraspecies variation in the percent metabolic activity at the MEC and MMC. This biological variation may reflect real differences in the degree of pharmacologic inhibition caused by caspofungin for different species or isolates.
Whether the greater degree of metabolic inhibition for some species (A. flavus) or isolates translates into a better in vivo or even clinical response to caspofungin and potentially constitutes an alternative endpoint for the prediction of outcome other than the MEC is a matter of further study. In recent studies of caspofungin activity in mouse models of invasive aspergillosis, survival was different among groups infected with Aspergillus isolates with the same or comparable MEC values, suggesting that the MEC was not a good predictor of in vivo response to caspofungin and that other factors may play a role (4, 7). Furthermore, in a study by Cacciapuoti et al. (7), mice infected with A. flavus appeared to have a better survival after caspofungin treatment than those infected with A. fumigatus; this difference, however, should be interpreted with caution since the duration of treatment and the day of assessment were different between the two species. Compatible with the greater reduction in percent metabolism at MEC and MMC for A. flavus (Table 1), Bowman et al. (5) also reported that caspofungin induced a significantly greater microbiological reduction, measured by PCR, in the kidneys of a murine model of disseminated aspergillosis of A. flavus than that of A. terreus. However, this microbiological reduction did not correlate well with survival. Notably, in a study of caspofungin used as salvage treatment for invasive aspergillosis, microbiological eradication was achieved in 54% of 13 patients with A. flavus infection versus 28% of 47 patients with A. fumigatus infection (13).
A paradoxical increase in metabolic activity at higher caspofungin concentrations was demonstrated for approximately half of the A. fumigatus and A. terreus isolates but only one of the A. flavus isolates. Wiederhold et al. observed a similar increase for A. fumigatus (28). These and other investigators also reported a trend for attenuation of antifungal activity with higher concentrations of caspofungin in animal models of invasive aspergillosis (21, 28). A paradoxical effect at comparable caspofungin concentrations has been reported as well for Candida isolates in vitro (22, 24). In the case of Candida, however, these concentrations were well above the MIC, whereas for Aspergillus they were above the MEC but still below the MICs. The paradoxical growth of Candida isolates in the presence of high caspofungin concentrations was recently associated with an increase in cell wall chitin content (23) and was not reproducibly demonstrated in vivo (8).
The precise mechanism of this paradoxical response among Aspergillus isolates is not yet understood. Gardiner et al. (10) described a class of spontaneous mutant A. fumigatus strains displaying a biphasic growth phenotype, with sensitivity to low concentrations of caspofungin but nearly normal growth at concentrations of >0.5 μg/ml, suggesting the induction of some resistance mechanisms. At high drug concentrations (≥16 μg/ml) the sensitivity was restored. This phenotype was not due to mutations in the AfFKS1 gene; preliminary studies suggested instead that exposure of the mutant strains to caspofungin may trigger some type of signaling pathway, resulting in the upregulation of cell wall proteins (10). Given the similarity of this biphasic growth phenotype with the paradoxical response observed in a number of our isolates, it is likely that the latter share common features with the mutant strains characterized by Gardiner et al., i.e., upregulation of cell wall components in the presence of caspofungin. Recently, the paradoxical effect in A. fumigatus was associated with increased expression of mitogen-activated protein kinase A in the presence of 8 μg of caspofungin/ml (N. P. Wiederhold, B. L. Wickes, and T. F. Patterson, Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-364, 2006).
The XTT assay for Aspergillus spp. is relatively simple and can be performed in most clinical laboratories. Calculation of the percent metabolic activity for each drug concentration, including the MEC and MMC, requires minimal training and can be performed quickly in an Excel worksheet. Subsequent objective and automated determination of X-MEC with this method can be achieved without modeling, using the cutoff values in Table 2. This assay, however, has limitations: (i) an additional 2-h incubation time until determination of X-MEC, (ii) preparation of solutions, and (iii) the cost associated with purchase of the reagents.
Modeling of data for research purposes, on the other hand, requires the use of appropriate initial values for application of the bell-shaped model. Use of the models described here generates descriptive quantitative parameters pertaining to the metabolic changes induced by caspofungin, and possibly other echinocandins, on Aspergillus spp., such as the EC50, the slope of the curves, and the maximal and minimal metabolic activity. These parameters may then be useful for inter- or intraspecies comparisons, antifungal drug combination studies (assessing concentration-dependent interactions), pharmacokinetic/pharmacodynamic modeling, and ultimately studies of in vitro-in vivo correlation.
In conclusion, the use of a lower menadione concentration allowed the detection and quantification of concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus spp., as well as the determination of X-MEC with the XTT assay. The inter- and intraspecies differences in the degree of metabolic inhibition and in the presence of paradoxical effect, revealed within a range of clinically achievable concentrations, could potentially correlate with in vivo or clinical outcome and warrant further investigation. Finally, the assessment and modeling of changes in fungal metabolism may provide quantitative endpoints that could be useful for in vitro studies of caspofungin activity, alone or in combination, against Aspergillus spp.
FIG. 1.
FIG. 1. Concentration-dependent changes in metabolic activity of Aspergillus spp. in the presence of increasing concentrations of caspofungin, as assessed by the XTT method using different concentrations of menadione (MEN). With 6.25 μM menadione, a significant reduction in fungal metabolism was detected at caspofungin concentrations greater than or equal to the MEC. Measurements from a single replicate per isolate are presented.
FIG. 2.
FIG. 2. Concentration-effect curves of metabolic activity in the presence of increasing concentrations of caspofungin, generated with the sigmoid Emax model for A. flavus (A) and the bell-shaped model for A. fumigatus (B). The parameters calculated by the two models (with the exception of the slope factors) are presented in the graph. The proximity of the EC50 (or EC50-1) and microscopic MEC values (<1 dilution) can be seen. The data represent the mean of three replicates.
FIG. 3.
FIG. 3. Comparison of the bell-shaped (solid line) and Gaussian (dashed line) models for description of the concentration-dependent effects of caspofungin on the metabolic activity of an A. terreus isolate demonstrating the paradoxical effect. The asymmetric nature of the biphasic response in the case of caspofungin is not adequately described by the symmetric Gaussian curve.
TABLE 1.
TABLE 1. Median metabolic activities (percentage of drug-free control) detected at the MEC, the MMC, and 8 μg of caspofungin/ml for Aspergillus spp.a
Species (no. of strains)Median (range)   No. of isolates with paradoxical increase% Metabolism at 8 μg/ml (range)
 MEC (μg/ml)% Metabolism at MECMMC (μg/ml)% Metabolism at MMC  
A. fumigatus (9)0.5 (0.25-0.5)42 (26-73)0.75 (0.5-2)28 (16-46)5 of 951 (18-77)c
A. terreus (12)0.5 (0.25-0.5)53 (25-79)1 (0.5-4)38 (22-67)6 of 1257 (23-85)c
A. flavus (8)0.25 (0.25-0.5)25 (12-32)b2 (0.5-8)17 (9-21)b1 of 820 (7-29)
a
The values for the MEC, MMC, and the numbers of isolates demonstrating a paradoxical increase in metabolic activity at higher concentrations are also presented.
b
, P < 0.01 compared to the corresponding percent metabolic activity of A. fumigatus or A. terreus.
c
, P < 0.001 compared to the percent metabolism at the MMC.
TABLE 2.
TABLE 2. Cutoff levels of metabolic activity (percentage of drug-free control) for determination of the X-MEC with the optimized XTT assay and the percent relative agreement (± one dilution) between the X-MEC and microscopic MEC
Species (no. of strains)Cutoff level (% metabolic activity)% Relative agreementa (SE)
A. fumigatus (9)60100 (0)
A. terreus (12)6593 (5)
A. flavus (8)40100 (0)
a
Three experiments were performed for each isolate.

Acknowledgments

This study was supported by the Intramural Research Program of the National Cancer Institute.

REFERENCES

1.
Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother.44:2310-2318.
2.
Antachopoulos, C., J. Meletiadis, E. Roilides, T. Sein, D. A. Sutton, B. L. Wickes, M. G. Rinaldi, W. G. Merz, Y. R. Shea, and T. J. Walsh. 2006. Relationship between metabolism and biomass of medically important zygomycetes. Med. Mycol.44:429-438.
3.
Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother.45:327-330.
4.
Barchiesi, F., E. Spreghini, A. Santinelli, A. W. Fothergill, S. Fallani, E. Manso, E. Pisa, D. Giannini, A. Novelli, M. I. Cassetta, T. Mazzei, M. G. Rinaldi, and G. Scalise. 2005. Efficacy of caspofungin against Aspergillus terreus. Antimicrob. Agents Chemother.49:5133-5135.
5.
Bowman, J. C., G. K. Abruzzo, A. M. Flattery, C. J. Gill, E. J. Hickey, M. J. Hsu, J. Nielsen Kahn, P. A. Liberator, A. S. Misura, B. A. Pelak, T. C. Wang, and C. M. Douglas. 2006. Efficacy of Caspofungin against Aspergillus flavus,Aspergillus terreus, and Aspergillus nidulans. Antimicrob. Agents Chemother.50:4202-4205.
6.
Burnham, K. P., and A. D. 2002. model selection and multimodel inference: a practical information-theoretic approach, 2nd ed. Springer-Verlag, New York, NY.
7.
Cacciapuoti, A., J. Halpern, C. Mendrick, C. Norris, R. Patel, and D. Loebenberg. 2006. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother.50:2587-2590.
8.
Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother.50:1293-1297.
9.
Espinel-Ingroff, A. 2003. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol.41:403-409.
10.
Gardiner, R. E., P. Souteropoulos, S. Park, and D. S. Perlin. 2005. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol.43(Suppl. 1):S299-S305.
11.
Kartsonis, N. A., J. Nielsen, and C. M. Douglas. 2003. Caspofungin: the first in a new class of antifungal agents. Drug Resist. Update6:197-218.
12.
Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-d-glucan synthase. Antimicrob. Agents Chemother.38:1480-1489.
13.
Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39:1563-1571.
14.
Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol.39:3402-3408.
15.
Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol.39:4256-4263.
16.
Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347:2020-2029.
17.
Motulsky, H. J., and A. Christopoulos. 2003. Complex dose-response curves, p. 290-295. In H. J. Motulsky and A. Christopoulos (ed.), Fitting models to biological data using linear and nonlinear regression. GraphPad Software, Inc., San Diego, CA.
18.
Motulsky, H. J., and A. Christopoulos. 2003. Introduction to dose-response curves, p. 256-265. In H. J. Motulsky and A. Christopoulos (ed.), Fitting models to biological data using linear and nonlinear regression. GraphPad Software, Inc., San Diego, CA.
19.
NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. Document M38-A. NCCLS, Pennsylvania, PA.
20.
Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol.42:3475-3482.
21.
Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother.46:12-23.
22.
Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother.48:3407-3411.
23.
Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother.50:3160-3161.
24.
Stevens, D. A., T. C. White, D. S. Perlin, and C. P. Selitrennikoff. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis.51:173-178.
25.
Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother.46:739-745.
26.
van Vianen, W., S. de Marie, M. T. ten Kate, R. A. Mathot, and I. A. Bakker-Woudenberg. 2006. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J. Antimicrob. Chemother.57:732-740.
27.
Walsh, T. J., P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother.49:4536-4545.
28.
Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis.190:1464-1471.
29.
Yekutiel, A., I. Shalit, Y. Shadkchan, and N. Osherov. 2004. In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother.48:3279-3283.

Information & Contributors

Information

Published In

cover image Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Volume 51Number 3March 2007
Pages: 881 - 887
PubMed: 17145783

History

Received: 15 September 2006
Revision received: 4 November 2006
Accepted: 27 November 2006
Published online: 1 March 2007

Permissions

Request permissions for this article.

Contributors

Authors

Charalampos Antachopoulos
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
Joseph Meletiadis
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
Tin Sein
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
Emmanuel Roilides
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
Third Department of Pediatrics, Aristotle University, Hippokration Hospital, Thessaloniki, Greece
Thomas J. Walsh [email protected]
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland

Metrics & Citations

Metrics

Note:

  • For recently published articles, the TOTAL download count will appear as zero until a new month starts.
  • There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
  • Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Figures

Tables

Media

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy